Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
DOB-CR AI simulator
(@DOB-CR_simulator)
Hub AI
DOB-CR AI simulator
(@DOB-CR_simulator)
DOB-CR
DOB-CR, or DOB/CR, , an acronym of "DOB-conformationally restrained", also known as 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the tetrahydroisoquinoline family. It is a cyclized phenethylamine and a derivative of the psychedelic drugs 2C-B and DOB in which the side chain has been cyclized with the benzene ring to form a tetrahydroisoquinoline (THIQ) ring system.
The drug shows modest affinity for the serotonin 5-HT2A receptor. Its affinity (Ki) for the receptor was 242 to 250 nM, which is about 6-fold lower than that of DOB. In contrast to DOB, DOB-CR completely failed to substitute for DOM in rodent drug discrimination tests. In addition, behavioral disruption occurred at higher doses. These findings suggest that DOB-CR would lack psychedelic effects in humans. The drug also failed to substitute for dextroamphetamine and MDMA in rodent drug discrimination tests, suggesting lack of stimulant or entactogenic effects as well. However, DOB-CR fully substituted for the structurally related selective α2-adrenergic receptor ligand TDIQ (MDTHIQ or MDA-CR), albeit with about 4-fold lower potency than TDIQ itself.
DOB-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.
DOB-CR
DOB-CR, or DOB/CR, , an acronym of "DOB-conformationally restrained", also known as 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the tetrahydroisoquinoline family. It is a cyclized phenethylamine and a derivative of the psychedelic drugs 2C-B and DOB in which the side chain has been cyclized with the benzene ring to form a tetrahydroisoquinoline (THIQ) ring system.
The drug shows modest affinity for the serotonin 5-HT2A receptor. Its affinity (Ki) for the receptor was 242 to 250 nM, which is about 6-fold lower than that of DOB. In contrast to DOB, DOB-CR completely failed to substitute for DOM in rodent drug discrimination tests. In addition, behavioral disruption occurred at higher doses. These findings suggest that DOB-CR would lack psychedelic effects in humans. The drug also failed to substitute for dextroamphetamine and MDMA in rodent drug discrimination tests, suggesting lack of stimulant or entactogenic effects as well. However, DOB-CR fully substituted for the structurally related selective α2-adrenergic receptor ligand TDIQ (MDTHIQ or MDA-CR), albeit with about 4-fold lower potency than TDIQ itself.
DOB-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.
Recent media
Recent media